Study results show a low 2.6% recurrence rate and clinically meaningful improvement in patient quality of life
MALVERN, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced the publication of the 24-month analysis from the BRAVO Study in Annals of Medicine and Surgery.
TELA Bio’s prospective, single-arm, multi-center clinical trial was designed to evaluate the clinical performance of OviTex 1S with permanent polymer embroidery for primary or recurrent ventral hernias in 92 enrolled patients. This study included real-world clinical scenarios as OviTex 1S was utilized in open and minimally invasive procedures, various planes of placement, and various CDC wound classes. OviTex 1S Permanent demonstrated a 2.6% recurrence rate in ventral hernias repaired using open, laparoscopic, or robotic techniques at the 24-month time point. In addition, patient quality of life assessments showed statistically significant and clinically meaningful improvement from baseline as early as 3-months post-surgery and continued at the 12 and 24-month timepoints. Surgical site occurrences (SSOs) were observed in 38% of the study population, where 78% of all enrolled patients were characterized as high risk for experiencing an SSO based on at least one known risk factor. These risk factors included obesity, active smoking, COPD, diabetes mellitus, coronary artery disease, or advanced age (≥75 years).
“I want to thank the entire investigator team for their diligence in completing this important study,” said principal investigator, Dr. George DeNoto III, MD, FACS, Director of General Surgery at St. Francis Hospital in New York. “Hernia implant design is continually evolving and it’s critical that the surgeon community is committed to generating research on the clinical safety and efficacy of newer implants. Our results provide evidence that OviTex 1S Permanent in ventral hernia repair results in a low rate of recurrence and improved quality of life for patients over a two-year period.”
Over 400,000 ventral hernia repairs are performed in the U.S. annually, most of which require the use of a reinforcement device. Permanent synthetic mesh is often used for ventral hernia repair, however the significant, long-term foreign body footprint may lead to chronic inflammation, infection, and persistent pain. OviTex Reinforced Tissue Matrix was designed to offer surgeons and patients an alternative to permanent synthetic mesh that minimizes the use of permanent synthetic materials to provide a more natural repair.
“We are very proud to share the full, final results of our BRAVO study,” stated Antony Koblish, President and CEO of TELA Bio. “Since the founding of TELA Bio we have been committed to validating the performance of OviTex from the bench-top to the OR. This commitment continues with our ongoing BRAVO II study which will evaluate the use of OviTex in robot-assisted ventral and inguinal hernia repairs.”
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
About OviTex®
OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Do not use OviTex in patients known to be sensitive to materials of ovine (sheep) origin. For prescription use only. For additional important safety information, please see the OviTex Reinforced Tissue Matrix Instructions for Use.
The statements made or results achieved by TELA Bio customers described herein were achieved in their specific setting. Due to variations in clinical experience and technique, there is no guarantee that these results are typical. A surgeon must use his or her own clinical judgment when deciding which products are appropriate for treatment of a particular patient. Always refer to the package insert, product label, and/or instructions for use before using any TELA Bio product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA’s management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others, that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data, that data from clinical studies using our product may not be indicative of outcomes in other surgical settings, and product defects or failures. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Greg Chodaczek
347-620-7010
ir@telabio.com
Media Contact
Alyson Kuritz
908-892-7149
alyson@0to5.com
Related Quotes
Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event.
Tricida only pursued a single drug candidate. That backfired spectacularly, but the drug developer deserves credit on one key measure.
The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial.
"Our strong results reflect growth of our in-line and new product portfolios," said CEO Giovanni Caforio.
Take action instead of just crossing off the days until you turn 65.
AbbVie's Humira, used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has been the world's top-selling drug for years. Now, Eli Lilly (NYSE: LLY) and Bristol Myers Squibb (NYSE: BMY) have blockbuster drugs in the works that could also change lives and boost their companies' fortunes. Lilly's Mounjaro (tirzepatide), a once-weekly injection, received its first Food and Drug Administration (FDA) approval in May as a therapy to treat type 2 diabetes, but the therapy also has huge potential as a weight-loss drug.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
The good news keeps coming in for Biogen (NASDAQ: BIIB). On Tuesday, the drugmaker reported its third-quarter results, and for the first time in a while, investors found something in one of its earnings updates to cheer about.
Is Pfizer stock a buy or a sell after finishing its acquisitions of GBT and Biohaven? Is PFE stock a buy or a sell right now?
Nobody will accuse Cytokinetics of being an overnight success, its chief executive says. But CYTK stock trades with enthusiasm on a near goal.
(Reuters) -Biogen Inc on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co and Roche. The drug, lecanemab was shown to slow the progress of the disease by 27% in a trial last month, and additional data is expected next month. Lecanemab and experimental drugs for the mind-wasting disease from Lilly and Roche belong to a class of treatments that reduces amyloid beta proteins in the brain believed to be an underlying cause of Alzheimer's.
When it comes to Medicare, understanding your healthcare needs and finding the right coverage are essential. But as you get close to or enter retirement, making decisions about your health can be overwhelming. To make the process a little easier, Vanguard … Continue reading → The post Vanguard's 3 Steps to Maximizing Your Medicare Coverage appeared first on SmartAsset Blog.
When it comes to healthcare spending, 'consumers can only really choose between paying up or walking away,' one analyst told MarketWatch.
Increasing expenses amid inflation is shrinking margins for the Zacks Medical-Hospital industry players. However, HCA Healthcare (HCA), Acadia Healthcare (ACHC), Universal Health (UHS) and Tenet Healthcare (THC) are poised to win big with recovering patient volumes.
The Anglo-Swedish pharma giant said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations.
Microcap company's proprietary process for growing THC and CBD in the lab follows the launch of its Vinia food supplement.
A billing expert was able to cut down her husband's hospital bill, but it wasn't easy. How do you fix incorrect medical charges on surprise billing?
The products were recalled due to "potentially elevated levels" of benzine.
The rehab center would provide post-hospital, inpatient neuro and physical rehabilitation specialty programs designed for recovery treatments.
Dove, Suave and Bed Head are among the aerosol dry shampoos recalled after they were found to contain benzene, which can cause cancer.